Lifeward ($LFWD) Stock Hub: Can New Leadership Scale ReWalk’s Commercial Momentum?

01 Executive answer

Lifeward is one of those rare public companies whose product can be historically important without the equity having produced a durable commercial success.

ReWalk helped create the modern powered medical exoskeleton category. It was born from a founder’s personal experience with paralysis, reached rehabilitation centers in 2011, gained a European CE mark for personal use in 2012, and in June 2014 became the first powered exoskeleton cleared by the U.S. Food and Drug Administration for personal use by eligible individuals with spinal cord injury. The product gave selected users the ability to stand, walk with crutches, sit, turn and, following later regulatory expansion, navigate stairs and curbs. It was not science fiction. It was a real medical device with a real emotional and functional impact.

Commercially, however, ReWalk entered one of the hardest possible medical-device markets. The addressable patient pool is much smaller than the total spinal-cord-injury population because candidates need sufficient upper-body strength, bone health, joint mobility, cognitive capacity and the ability to complete extensive training. The device is expensive, requires fitting, service, reimbursement work and often a trained companion. It competes not only against other exoskeletons, but against the wheelchair’s speed, reliability, familiarity and low daily friction. For years, the absence of broad reimbursement turned each sale into a prolonged individual project rather than a repeatable consumer transaction.

Lifeward has made genuine progress. The U.S. Department of Veterans Affairs created a national procurement pathway in 2015. Germany added ReWalk to its medical-aids directory in 2018 and later developed insurer-specific procurement agreements. The FDA cleared stair and curb use in 2023. Medicare classified personal exoskeletons within the brace benefit and established a 2024 K1007 purchase fee-schedule amount of $91,031.93, commonly rounded to $91,032. ReWalk 7 received FDA clearance in March 2025. Major Medicare Advantage plans and BARMER in Germany expanded defined coverage processes. These are material achievements that improve access and reduce one of the original business model’s largest barriers.

Yet the financial evidence remains difficult. Revenue increased sharply after the 2023 acquisition of AlterG but fell again in 2025. Lifeward has continued to post heavy operating losses and cash burn, entered 2026 with only $2.2 million in unrestricted cash, completed a second reverse split in two years, and then accepted a transformative Oramed transaction that introduced convertible debt, warrants, pre-funded warrants, revenue-sharing obligations and potential ownership concentration. The July 2026 financing added more secured convertible notes and warrants at a $5.40 conversion or exercise price. These financings may support operations and expansion, but they make the fully diluted capital structure far more important than the basic share count or the screen-quoted market capitalization.

The investment question is therefore no longer simply whether ReWalk is a valuable technology. It is whether Lifeward can finally convert reimbursement into sustained unit growth, stabilize AlterG, launch an upper-body exoskeleton with better unit economics, and capture value from the acquired Protein Oral Delivery platform without losing that value through dilution, debt, execution failures or an identity crisis between medical devices and drug development. The second quarter of 2026, reported on August 14, gave the first part of that answer: revenue of $6.623 million, up 16% and the strongest quarter since the end of 2024, with AlterG up 25% and ReWalk Personal up 13%. It also showed how narrow the base is—the improvement came from the United States and from Europe outside Germany—and it arrived in the same filing as the resignation of three directors and the departure of the chief financial officer.

What is genuinely stronger now

Medicare reimbursement exists; ReWalk 7 is cleared; U.S. Medicare Advantage and German coverage processes have expanded; ReWalk revenue grew in the fourth quarter of 2025 and again partially offset AlterG weakness in the first quarter of 2026; an upper-body program and new distribution channels create additional shots on goal.

What remains structurally dangerous

The company is still loss-making, cash-hungry and dependent on external capital. The capital structure contains large potential dilution relative to the basic share base. AlterG shipments have been affected by working-capital constraints, and the new oral-insulin strategy introduces a very different development risk profile.

02 Financial and ownership snapshot

Market data are snapshots, while share counts and financing terms come from SEC filings. Some quote services display a materially different market capitalization because they appear to use the weighted-average basic share count from the earnings-per-share calculation—2,796,621 for the second quarter of 2026, and 2,210,280 for the first half—instead of the 2,832,016 ordinary shares reported outstanding as of August 12, 2026. A weighted-average EPS denominator is not the correct denominator for a point-in-time market-cap calculation. Financial figures are derived from Lifeward’s 2025 Form 10-K, the Q2 2026 Form 10-Q, Exhibit 99.1 to the Form 8-K filed August 14, 2026, and the July 2026 Form 8-K.

03 1. The origin story: a problem worth trying to solve

The ReWalk story began long before Lifeward became a public micro-cap. It began with the gap between what a wheelchair does extraordinarily well and what it cannot provide: upright mobility.

Dr. Amit Goffer, an Israeli engineer and entrepreneur, became quadriplegic after an accident in 1997. He founded the company that would become ReWalk in 2001. At the time, the idea of a wearable powered exoskeleton for personal use sat somewhere between advanced engineering, rehabilitation research and science fiction. Industrial robots were established, but building a battery-powered system that could be worn over a paralyzed user’s legs, respond to intentional movement, remain balanced through crutches and operate in real environments was a different problem entirely.

The device that emerged used powered hip and knee joints, sensors, software, rechargeable batteries and a wrist-worn controller. The user initiated walking through commands and subtle forward shifts of the upper body. The system detected the shift and moved one leg, after which repeated weight transfers created a sequence of steps. The design did not restore neurological function. It provided mechanical ambulation to a carefully selected user who retained sufficient upper-body control.

That distinction matters. ReWalk was never a cure for paralysis, and it never eliminated the wheelchair. It was an assistive medical device that enabled a different mode of movement. Its value could include standing at eye level, walking during selected daily activities, exercise, potential secondary health benefits and a powerful psychological effect. But its practical limitations were present from the start: users still needed crutches, training, suitable terrain, adequate bone density and a body capable of safely carrying out the task.

Development took more than a decade. In 2011, the company launched ReWalk Rehabilitation for hospitals and rehabilitation centers in the United States and Europe. This adjustable multi-user system served two functions. It gave clinics a robotic gait-training tool, and it created a pathway through which potential personal users could discover whether they were suitable candidates. In late 2012, ReWalk Personal began marketing in Europe after CE-mark clearance. By August 2014, the company reported that it had placed 62 Rehabilitation systems and 19 Personal systems and had trained more than 400 users across more than 20,000 hours of use.

Those numbers revealed both sides of the story. They were remarkable for a new category of wearable robotics, but tiny in commercial terms. Even before the IPO, ReWalk was demonstrating that medical-device innovation and scalable adoption are not the same thing.

04 2. The complete ReWalk-to-Lifeward timeline

1997

Engineer Amit Goffer is paralyzed in an accident. His experience becomes the personal and technical catalyst for developing a wearable system capable of enabling upright ambulation.

2001

Goffer founds the Israeli company originally known as Argo Medical Technologies. The company begins the long development process that will produce ReWalk.

2011

ReWalk Rehabilitation launches in U.S. and European hospitals and rehabilitation centers. It is adjustable for multiple patients and acts as both a therapy platform and a gateway to personal use.

Late 2012

ReWalk Personal begins commercial marketing in Europe after receiving CE-mark clearance.

June 2014

The FDA grants de novo authorization for ReWalk, creating the Class II powered-exoskeleton category and permitting home and community use for qualified individuals with spinal cord injury under specified conditions.

September 2014

ReWalk Robotics completes its Nasdaq IPO under ticker RWLK, selling 3.0 million shares at $12 and an additional 450,000 shares through the underwriters’ option. Net proceeds were approximately $36.3 million.

2015

The U.S. Department of Veterans Affairs establishes a national policy for evaluating, training and procuring personal exoskeletons for qualified veterans with spinal cord injury. The policy becomes one of the first meaningful reimbursement frameworks.

2016

ReWalk deepens its collaboration with Harvard’s Wyss Institute and Biodesign Lab on soft exosuit technology, seeking a lighter system for stroke and other gait impairments.

June 2018

ReWalk Personal 6.0 is added to Germany’s official medical-aids directory under code 23.29.01.2001. This creates formal recognition within the statutory insurance system, though procurement still requires clinical and administrative work.

June 2019

The FDA clears ReStore, a lightweight powered soft exosuit for gait rehabilitation in people with hemiplegia or hemiparesis after stroke.

2020

ReWalk begins distributing MYOLYN MyoCycle functional electrical stimulation systems in the United States, expanding beyond exoskeletons through a partner product.

March 2023

The FDA clears ReWalk Personal for stairs and curbs, an important step toward real-world utility. The feature had already been used in Europe and was supported by European real-world data.

August 2023

ReWalk acquires AlterG for approximately $19 million in cash plus potential earnouts. The deal adds a larger installed base of anti-gravity treadmill systems and immediately broadens revenue.

November 2023

CMS finalizes the policy that places personal exoskeletons within the Medicare brace benefit category, creating a national benefit pathway effective January 1, 2024.

January 2024

The operating brand becomes Lifeward and Nasdaq trading moves from RWLK to LFWD. The new identity reflects a portfolio broader than the original ReWalk device.

April 2024

CMS adds the 2024 K1007 purchase fee-schedule amount for personal exoskeletons: $91,031.93, commonly rounded to $91,032.

September 2024

The legal corporate name formally changes from ReWalk Robotics Ltd. to Lifeward Ltd.

March 2025

The FDA clears ReWalk 7, adding cloud connectivity, an updated interface, crutch-mounted controls, customizable walking speeds and integrated stair and curb activation.

2025

Lifeward signs a defined reimbursement agreement with BARMER in Germany, expands U.S. Medicare Advantage coverage, restructures its commercial model, reduces spending and shifts MYOLYN away from its prior exclusive-distribution emphasis.

December 2025

A distribution agreement with Verita Neuro opens Mexico, Thailand and the United Arab Emirates through an intensive inpatient training model.

February 2026

Lifeward agrees to acquire Skelable upper-body exoskeleton assets and engineering expertise. Management targets a potential commercial launch approximately 18 to 24 months after development and regulatory work.

February 2026

The company executes a 1-for-12 reverse share split after a 1-for-7 split in March 2024, producing a cumulative 1-for-84 consolidation over two years.

March 2026

Lifeward closes the Oramed/Oratech transaction, acquires the Protein Oral Delivery platform and oral-insulin program, receives cash and financing, and issues a large package of shares, pre-funded warrants and warrants.

Q2 2026

A collaboration with Shirley Ryan AbilityLab begins dedicated clinic days intended to streamline ReWalk evaluation, fitting and conversion from interest to real-world use.

July 2026

Lifeward closes an additional $5.58 million senior secured convertible-note financing with matching warrants and a possible second $5.58 million tranche tied to ReWalk sales growth or a sustained share-price condition.

August 3 and 10, 2026

Lifeward files a Form S-3 registering the resale of 2,066,662 ordinary shares underlying the July notes and warrants. The registration becomes effective on August 10.

August 14, 2026

Second-quarter results: revenue of $6.623 million, up 16%, with cash of $9.448 million at June 30 and a pro-forma position of approximately $11 million. The same day, the company discloses that chairman Robert J. Marshall Jr. and directors Michael Swinford and William Mark Sigsbee stepped down effective August 13, and that chief financial officer Almog Adar will leave effective September 30.

05 3. What made ReWalk innovative

ReWalk’s historical importance rests on three achievements. First, it miniaturized powered lower-limb robotics into a wearable system. Second, it transferred the exoskeleton concept from a laboratory or clinic into personal home and community use. Third, it persuaded regulators to create a pathway for a type of device that had no true predecessor.

The original FDA de novo decision did more than clear one product. It established “powered exoskeleton” as a Class II medical-device category. The authorization described a prescription orthosis placed over the lower limbs and part of the torso, with powered hip and knee movement, a control system, sensors and a required training program. The FDA also identified the central risks: instability, falls, fractures, skin injury, electrical or software failure, misuse and the consequences of improper fitting.

The personal device is custom configured for the user. It does not simply attach to anyone with paralysis. The person must satisfy clinical criteria and complete training. Historically, candidates needed healthy hands and shoulders capable of supporting crutches or a walker, sufficient bone density, no unstable fractures, the ability to stand using a standing frame, suitable height and weight, and generally good health. Cognitive or psychiatric conditions that could interfere with safe operation, severe spasticity, significant contractures, pregnancy and other medical conditions can exclude a candidate.

In use, the technology does something emotionally powerful: it allows a person who ordinarily navigates life from a wheelchair to rise, face others at eye level and take powered steps. That visual impact helped ReWalk attract media attention, research interest and public-market enthusiasm. The stories of users walking at ceremonies, standing at weddings or navigating public environments are not marketing abstractions. They reflect a meaningful change in selected moments of life.

But the system’s engineering success also illustrates why robotics adoption is difficult. The user is not passive. Walking requires concentration, coordinated weight shifting, crutch management and awareness of terrain. Speed is lower than normal walking and usually lower than efficient wheelchair travel. Putting on and removing the device takes time. Batteries, annual inspections, software, replacement parts and service matter. A device that functions in a demonstration must also function after years of real use, across homes, sidewalks, clinics and insurance processes.

Stairs and curbs: a practical rather than cosmetic upgrade

The 2023 FDA clearance for stairs and curbs was important because the original U.S. authorization excluded stair climbing. A personal mobility device that stops at every curb or staircase has an obvious limit in real environments. Lifeward supported the expansion with European real-world experience, including a cohort of 47 users and more than 18,000 stair steps collected over more than seven years.

The feature did not turn ReWalk into unrestricted independent walking. Users still required training and appropriate support. Nevertheless, it reduced a major mismatch between the product’s “community use” aspiration and the built environment. ReWalk 7 later integrated the activation process more seamlessly.

ReWalk 7: modernization rather than a new category

ReWalk 7, cleared in March 2025, is the newest generation of the core platform. Its cloud connectivity can support data capture, service and potentially payer evidence. A crutch-mounted push button reduces dependence on a separate wrist interaction. Customizable walking speeds and a revised interface may improve fitting and user experience. Seamless stair and curb activation reduces workflow friction.

These upgrades are commercially relevant because medical-device adoption is often won through small reductions in inconvenience rather than one spectacular technical leap. ReWalk 7 does not expand the product to every person with spinal cord injury, but it can improve the experience for those who already qualify and make the platform easier for clinics to manage.

06 4. Why a revolutionary product remained a difficult niche

The largest analytical mistake in the ReWalk story is to calculate the market from the total number of people living with spinal cord injury and then multiply that population by the device price. The real commercial funnel is radically narrower.

Patient eligibility is selective

Many individuals with spinal cord injury cannot safely use a personal lower-body exoskeleton. Cervical injuries may impair the arms and hands needed for crutches. Osteoporosis or low bone density can increase fracture risk. Contractures, severe spasticity, body dimensions, pressure injuries, cardiovascular limitations, balance, cognition and other conditions can exclude or delay use. Even within the eligible population, not everyone wants the device or sees enough daily value to justify the training burden.

The wheelchair is not merely the default because exoskeletons were unavailable. Modern wheelchairs are fast, efficient, familiar and adaptable. An exoskeleton can provide upright exercise and selected ambulation, but it generally does not replace the wheelchair for long-distance mobility, workday efficiency or complex terrain. The relevant question for a patient is therefore not “Would walking be desirable?” It is “Will I use this particular system frequently enough, safely enough and meaningfully enough to justify months of evaluation, fitting and training?”

The price creates an institutional transaction

CMS’s $91,031.93 K1007 purchase fee-schedule amount—commonly rounded to $91,032—illustrates the economic scale. At that level, a ReWalk purchase is not comparable to a consumer wellness device. It is closer to a complex durable-medical-equipment procurement. The sale can involve physicians, therapists, documentation, medical-necessity review, prior authorization, appeals, a payer, a supplier, fitting, training, warranty and ongoing service.

Before broad Medicare reimbursement, many personal systems depended on self-pay, legal settlements, donations, workers’ compensation, veterans’ benefits or case-by-case insurer decisions. That process created long sales cycles and unpredictable revenue recognition. It also meant that demand could exist without becoming booked revenue.

Training is part of the product

ReWalk is not shipped in a box and activated through an app. A user must be evaluated, fitted and trained by qualified personnel. The training network is therefore part of Lifeward’s commercial infrastructure. Every geographic expansion requires more than a distributor: it requires clinical partners capable of screening candidates, teaching safe use and supporting documentation.

This is one reason the Shirley Ryan AbilityLab collaboration and Verita Neuro model matter. Dedicated evaluation days can reduce the number of disconnected steps between interest and qualification. Intensive inpatient training can compress a process that otherwise unfolds over repeated outpatient visits. Neither model guarantees high conversion, but both address a known bottleneck.

Clinical evidence is meaningful but heterogeneous

Published studies support the feasibility of powered-exoskeleton walking and report potential benefits involving physical activity, bowel function, pain, spasticity, body composition and psychosocial well-being. A 2016 meta-analysis found that powered exoskeletons could enable ambulation in real-world settings and generate exercise intensity compatible with prolonged use. Small home and community studies have shown that trained participants can use the device outside the laboratory.

The evidence base nevertheless has limitations: small samples, selected participants, different devices, short follow-up and outcomes that may not translate directly into reduced healthcare costs. Some claimed secondary benefits remain difficult to quantify at the level payers require. An emotional or functional benefit for an individual can be real even when a health-economic model remains uncertain.

Lifeward has also presented long-term safety data. At ASIA 2026, the company reported low fracture prevalence across a global data set and no fractures among a German cohort of 97 users since 2018. Those data are encouraging, but readers should recognize that they were presented by the company and should be assessed alongside peer-reviewed and independent evidence.

Reimbursement solves access, not every commercial problem

Medicare coverage is the most important commercial development in ReWalk’s history, but coverage is not the same as automatic payment. The company still needs medically eligible candidates, physician support, complete documentation, prior authorization where applicable, successful training and a clean claim. Payment timing affects working capital. Denials or requests for additional information can stretch the cycle.

The key metric is therefore not theoretical covered lives. It is the number of reimbursed units delivered per quarter, the time from lead to placement, the cash-collection cycle and the contribution margin after reimbursement, training, service and sales expenses. Lifeward has reported record Medicare placement quarters, but total ReWalk revenue of $8.5 million in 2025 remained slightly below 2024. The fourth quarter improved by 20%, showing progress, but not yet proving a consistently accelerating curve.

The central commercial lesson

ReWalk’s market is not constrained by awareness alone. It is constrained by a chain of eligibility, desire, clinical capacity, reimbursement, training, fitting and payment. Lifeward wins only when the entire chain works.

07 5. The reimbursement odyssey

The Department of Veterans Affairs

The VA became an early institutional leader. Its 2015 national policy created a route for qualified veterans with spinal cord injury to be evaluated, trained and provided with a personal exoskeleton. A 2018 policy revision expanded training access through more VA locations and eligible private rehabilitation centers. The VA pathway was important not only for sales, but because it showed that a national payer could treat an exoskeleton as a legitimate assistive technology rather than a demonstration device.

Even so, VA adoption remained limited by the number of clinically eligible veterans and training availability. A national policy removes a major barrier, but it does not turn a narrow population into a mass market.

Germany: from case-by-case wins to structured procurement

Germany supplied some of the earliest reimbursement victories. Individual accident insurers approved systems, and in 2018 ReWalk 6.0 entered the official medical-aids directory. The listing gave the product a recognized code and established it as an eligible medical aid within statutory health insurance.

Later contracts with major insurers defined the evaluation and procurement process more clearly. The February 2025 BARMER agreement added a formal pathway for 8.5 million beneficiaries. Lifeward said that, after the agreement, approximately 45% of Germany’s statutory-insurance population was covered by insurers with a defined reimbursement process for personal exoskeletons.

Germany is useful as a real-world commercial laboratory. It demonstrates that reimbursement can be built, but also that even a favorable national system requires insurer contracts, medical-service review and extended training. The market became more predictable, not effortless.

Medicare: the milestone that took nearly a decade

When ReWalk went public in 2014, management already recognized that broad U.S. reimbursement was essential. The original IPO filing warned that a CMS decision could take years. That warning proved accurate.

CMS’s 2023 Home Health final rule classified personal exoskeletons under the Medicare brace benefit, effective January 1, 2024. In April 2024, CMS added a $91,031.93 purchase fee-schedule amount for HCPCS code K1007, calculated through gap filling because the technology contained features that could not be described through existing comparable codes.

This solved three foundational questions: benefit category, coding and payment. It allowed physicians and suppliers to pursue claims with a defined national framework. Lifeward reported that Medicare Administrative Contractors began approving claims and that placements subsequently reached record quarterly levels.

The commercial test now shifts from policy creation to execution. Lifeward must build a repeatable funnel and prove that the economics of each reimbursed placement are attractive after all associated costs. It must also extend the logic beyond traditional Medicare. Coverage decisions by Aetna, Humana and UnitedHealthcare Medicare Advantage plans, representing approximately 16 million covered lives according to Lifeward, are part of that expansion.

08 6. Beyond ReWalk: the portfolio Lifeward assembled

ReStore: elegant technology, limited commercial weight

ReStore came from soft-robotics work associated with Harvard’s Biodesign Lab. Instead of a rigid frame powering the hips and knees, ReStore uses a lightweight textile structure and cable-driven assistance around the ankle to help people with hemiplegia or hemiparesis after stroke during supervised rehabilitation.

The FDA cleared ReStore in June 2019 for use in rehabilitation institutions by patients who can already walk at least five feet with no more than minimal to moderate assistance. The device is therefore a therapy tool, not a personal system for non-ambulatory community use.

Clinical publications have reported improvements in walking speed and distance, including a randomized study and follow-up work suggesting that gains after intensive training can persist beyond the treatment period. The technology is scientifically credible and potentially useful to therapists.

Commercially, however, ReStore did not become the scale engine investors once imagined. Rehabilitation centers must decide whether a specialized robotic system improves outcomes or workflow enough to justify capital spending, staff training and maintenance. The company recorded obsolete ReStore inventory write-downs during its 2025 manufacturing transition. That does not mean the clinical concept failed; it means the product’s commercial relevance has been modest relative to the resources once expected.

MYOLYN MyoCycle: portfolio breadth without ownership leverage

Lifeward began distributing MYOLYN functional electrical stimulation cycles in 2020. FES cycling activates paralyzed or weakened muscles through electrical impulses, allowing therapeutic cycling in clinics or at home. The product fits the company’s neurological rehabilitation channels and was available through VA pathways.

But distribution products typically provide less strategic control and lower long-term leverage than proprietary platforms. MyoCycle revenue fell 50% to approximately $0.6 million in 2025 and fell 90% year over year in the fourth quarter as Lifeward moved away from an exclusive arrangement and prioritized proprietary products. The decline is a reminder that adding catalog items can expand revenue temporarily without changing the company’s underlying economics.

AlterG: the acquisition that changed the revenue base

In August 2023, ReWalk paid approximately $19 million in cash to acquire AlterG, with additional earnouts tied to revenue growth. AlterG’s Anti-Gravity systems use differential air pressure to reduce a user’s effective body weight during treadmill walking or running. The technology originated from NASA-related concepts and is installed across rehabilitation clinics, hospitals, sports programs and performance facilities.

The strategic logic was understandable. AlterG served a much broader population than personal exoskeletons, had an installed base exceeding 4,000 facilities worldwide, generated recurring service revenue and gave ReWalk a larger commercial platform. It also diversified the company away from a single product whose sales depended on individual reimbursement.

The acquisition transformed reported revenue. Lifeward’s total revenue rose from $13.9 million in 2023, which included only a partial period of AlterG ownership, to $25.7 million in 2024. But the acquisition did not produce profitability. AlterG revenue then fell 18% to $12.9 million in 2025, and Q1 2026 shipments were constrained by working-capital and sourcing issues, before recovering to $4.1 million in the second quarter of 2026, up 25% year over year on United States unit shipments, service revenue and average selling prices.

This is a critical execution issue. Capital equipment requires inventory, components and manufacturing commitments before cash is collected. Lifeward disclosed $10.696 million in non-cancelable purchase obligations due within one year at June 30, 2026. At the same date, cash was $9.448 million. The figures are not directly netted against one another, but they show why working-capital management is central to the company’s survival and growth.

Lifeward closed AlterG’s Fremont operations and transferred production to contract manufacturer Cirtronics. It also transitioned ReWalk production away from Sanmina toward an in-house model. These moves may reduce costs, but manufacturing transitions can cause shipment timing problems, inventory write-downs, quality risk and lower factory absorption. Q1 2026’s 34.2% gross margin, down from 42.2% a year earlier, reflected lower volume, fixed-overhead absorption, tariffs and currency effects.

09 7. The rebrand: why ReWalk became Lifeward

The Lifeward name was introduced operationally in January 2024, with the Nasdaq ticker changing from RWLK to LFWD. The legal corporate name changed in September 2024. The rebrand was more than cosmetic. “ReWalk Robotics” described one flagship product; “Lifeward” was intended to describe a continuum of rehabilitation and recovery technologies.

The timing made strategic sense after AlterG. The company now sold rigid exoskeletons, a soft exosuit, anti-gravity treadmills and FES cycles. A broader identity could help cross-selling, channel partnerships and future acquisitions.

Yet rebranding creates a risk when the company’s strongest recognition remains attached to the original product. ReWalk is a memorable category pioneer. Lifeward is less specific. The company must preserve ReWalk’s credibility while showing that the parent organization can allocate capital across multiple technologies. The 2026 move into oral biologics pushes that challenge much further: Lifeward is no longer merely a diversified rehabilitation-device company.

10 8. The 2026 upper-body exoskeleton initiative

In February 2026, Lifeward agreed to acquire intellectual property, prototypes and related assets from Finland-based Skelable. The consideration was modest—approximately $480,000 in Lifeward equity payable in milestone-based installments plus nominal cash—but the strategic ambition is substantial.

The platform is designed to assist weakened or paralyzed arms and hands, initially targeting people with upper-limb impairment after stroke. The engineering group joining the project brings extensive exoskeleton and wearable-robotics experience. Lifeward has said the system integrates artificial-intelligence capabilities and could reach commercial launch approximately 18 to 24 months after continued development and regulatory approvals.

Upper-body rehabilitation may be commercially attractive for several reasons. Stroke is far more common than the subset of spinal cord injury suitable for ReWalk Personal. Loss of arm and hand function directly affects eating, dressing, hygiene, transfers, work and independent living. A device that assists repeated task-specific movement could fit rehabilitation clinics and, eventually, home therapy.

The reimbursement landscape may also be more favorable than starting from zero. CMS already has powered upper-limb orthosis pathways, although Lifeward will still need the correct product classification, clinical evidence, coding and coverage. The company believes it can reuse its regulatory, clinical and payer capabilities.

Investors should not treat the 18-to-24-month target as a guaranteed launch. The acquired technology was not a finished commercial product. Lifeward must complete engineering, usability, verification, clinical work, manufacturing design and regulatory submission. It must also prove that the device provides enough functional improvement to justify its price and therapist workflow. The program is promising precisely because it addresses a broader need, but it remains a development asset.

11 9. The Oramed transaction: a new company inside the old company

The most dramatic change in Lifeward’s history may not be an exoskeleton at all. In March 2026, the company closed a strategic transaction with Oramed Pharmaceuticals and acquired Oratech Pharma, including the Protein Oral Delivery technology platform and the ORMD-0801 oral-insulin program.

The platform is designed to deliver protein drugs orally rather than through injection. Oral insulin is the lead asset. The scientific objective is compelling: deliver insulin through the gastrointestinal tract in a way that exposes the liver before the peripheral circulation, potentially more closely approximating natural physiology and allowing earlier treatment in type 2 diabetes.

Oramed previously ran a large Phase 3 program that did not meet its primary endpoint. The new strategy is based on analyses intended to identify a more responsive population and optimize the trial design. Lifeward has described a planned 60-patient U.S. study. Oramed is expected to provide clinical-development and project-management services and to fund much of the development effort under the transaction structure.

This arrangement gives Lifeward optionality without requiring it to build an entire drug-development organization immediately. It also creates a path to value that is not tied to rehabilitation capital equipment. If a targeted oral-insulin study produces convincing data, the platform could attract partnership interest far beyond Lifeward’s current scale.

The risks are equally clear. Oral delivery of biologics is scientifically difficult. A prior Phase 3 failure cannot be ignored. Small post-hoc subgroups can generate hypotheses that do not reproduce prospectively. Drug trials operate on different timelines, regulatory standards and capital requirements than medical devices. The company now needs to communicate two very different stories to investors while maintaining focus on the commercial business that funds part of its operations.

Transaction economics and governance

The transaction was not a simple technology purchase. Lifeward issued 1,250,363 ordinary shares and pre-funded warrants for 1,006,113 shares, plus 1,296,296 freestanding warrants with a $5.40 exercise price. The company agreed to future revenue-sharing payments. The accounting value of the acquired assets was approximately $12.4 million, including $6.5 million of cash, approximately $1.0 million of prepaid clinical-trial services and $4.9 million allocated to in-process research and development, which was expensed immediately.

At closing, Oramed received instruments representing up to 49.99% of Lifeward’s fully diluted equity, while the number of ordinary shares issued at closing was limited to no more than 45% of outstanding ordinary shares immediately after closing. Certain board members are affiliated with Oramed. This concentration can align a strategic sponsor with the company, but it also gives Oramed significant economic and governance influence.

In parallel, Lifeward entered a financing agreement providing up to $20 million of senior secured convertible notes, including $10 million issued at closing, together with warrants. The March notes bear 8% interest, mature in March 2029 and are convertible at $5.40 per share, subject to terms and adjustments.

Management has discussed up to $47 million of potential financing support associated with the broader Oramed framework. Readers should not interpret that headline as $47 million of unrestricted cash already on the balance sheet. The total includes conditional or structured financing components, and each component can carry debt, conversion or ownership consequences.

12 10. The July 2026 financing: capital with a significant equity shadow

On July 6, 2026, Lifeward closed an additional financing involving $5.58 million in senior secured convertible notes and matching warrants. The company may issue a second $5.58 million tranche if it satisfies customary conditions and one of two commercial or market triggers.

The first trigger requires at least a 150% increase in ReWalk unit sales, measured in dollars, relative to the relevant trailing-twelve-month comparison. The second requires LFWD shares to close at or above $13.80 for ten consecutive trading days before the additional closing.

The notes mature three years after issuance and bear 8% annual interest, rising to 15% after an event of default. They convert at an initial $5.40 per share. The warrants cover up to 100% of the shares into which the notes were initially convertible, also at $5.40, and remain exercisable for five years. Conversion and exercise are subject to 4.99% beneficial-ownership limitations for each purchaser and a 19.99% exchange cap unless shareholders approve issuance above that limit.

The financing is not inherently negative. A small loss-making company needs capital to build inventory, support claims, fund upper-body development and maintain operations. The structure also ties the second tranche partly to strong ReWalk execution. But the notes are secured, carry interest and create a substantial number of potential shares and warrants at the documented initial conversion price of $5.40.

For LFWD, dilution analysis cannot stop at basic shares outstanding. At June 30, 2026—before the July instruments were issued—the company said that warrants, pre-funded warrants, share options, restricted stock units and convertible notes covering 7,064,612 shares were excluded from diluted earnings-per-share calculations because the company reported a loss. Twelve months earlier the same figure was 763,890. “Anti-dilutive” in accounting does not mean economically irrelevant. It only means those instruments were not included in the loss-per-share denominator for that period.

The initial July tranche adds approximately 1.033 million potential conversion shares and the same number of warrant shares at the initial $5.40 prices. On a simple gross-share-equivalent basis, the June 30 overhang plus the initial July tranche totals roughly 9.13 million potential shares, compared with 2,832,016 basic shares outstanding as of August 12, 2026. This is not a forecast that every instrument will convert or be exercised: ownership limits, the 19.99% exchange cap, expiration dates, market prices, cashless exercise provisions, interest accrual and future amendments all affect the outcome.

Capital structure: the equity shadow is several times the filed basic share count

Illustrative gross share equivalents based on the latest filed counts and initial July terms. The conditional tranche is shown separately and is not currently outstanding.

Basic: ordinary shares outstanding as of August 12, 2026.
Q2 potential: all securities excluded from diluted EPS at June 30, 2026.
July first tranche: note conversion plus matching warrant coverage.
Conditional tranche: shown only to illustrate the possible additional layer.

Capital-structure warning

The displayed market capitalization may make LFWD look extraordinarily small relative to its revenue and technology portfolio. That apparent cheapness can be deceptive. A proper valuation must model basic shares, pre-funded warrants, transaction warrants, legacy warrants, convertible notes, interest, possible cashless exercises, ownership caps, exchange caps and future financing needs.

13 11. Financial history: innovation has not yet become self-funding growth

2024: the reimbursement and acquisition surge

2024 was the strongest revenue year in the company’s history. Total revenue reached $25.7 million, compared with $13.9 million in 2023. ReWalk sales rose 130%, benefiting from Medicare claims and the establishment of a national reimbursement rate. AlterG contributed a full year instead of only the post-acquisition period.

But operating expenses and losses remained high. Lifeward recorded a large impairment charge associated with acquired intangible assets, and operating cash use reached approximately $21.7 million. The business demonstrated that it could grow revenue, but not yet that the growth would produce operating leverage.

2025: restructuring and a setback in the top line

Revenue fell to $22.0 million. ReWalk Personal generated approximately $8.5 million, down 3%. AlterG generated $12.9 million, down 18%, partly because a large international distributor had ordered more heavily in 2024 and was expected to resume in 2026. MyoCycle produced approximately $0.6 million, down 50%.

Gross margin improved on a reported basis to 38.2% from 32.0%, although adjusted gross margin fell to 40.9% from 42.7%. Total operating expenses declined 25% to $28.1 million, helped by restructuring, lower R&D after major device programs and more efficient sales and reimbursement spending. Adjusted operating loss narrowed to $15.1 million. Operating cash use improved to $16.8 million from $21.7 million.

The direction of expenses was encouraging, but the company still consumed cash at a rate that required financing. Lifeward ended 2025 with only $2.2 million in unrestricted cash and substantial doubt about its ability to continue as a going concern without additional capital.

Q1 2026: better cash, weaker operations, complex accounting

First-quarter revenue fell to $3.9 million from $5.0 million. AlterG weakness was the primary cause, while ReWalk improved. Gross margin fell to 34.2% because of lower volume, manufacturing overhead, tariffs and foreign exchange.

GAAP operating loss widened to $10.3 million, but approximately $4.9 million was a one-time acquired in-process R&D charge related to Oratech, and about $0.6 million represented transaction expenses. Non-GAAP operating loss was approximately $4.6 million, roughly consistent with the prior-year period.

Cash increased to $11.4 million, largely because the Oratech acquisition brought $6.5 million and the financing supplied additional capital. Operating cash use improved to $3.7 million from $5.5 million. That is a positive operational trend, but one quarter does not establish a sustainable runway, especially with purchase commitments, secured debt and new development programs.

Q2 2026: the best revenue quarter in eighteen months and the largest reported loss

Second-quarter revenue was $6.623 million against $5.724 million a year earlier, an increase of 16% and the highest quarterly figure since the fourth quarter of 2024. The composition matters more than the headline. AlterG products and services rose 25% to $4.1 million on United States unit shipments, service revenue and average selling prices, which is the recovery the previous quarter had been missing. ReWalk Personal exoskeletons rose 13% to $2.5 million, and the company attributes that improvement primarily to Europe rather than to the American reimbursement channel that has absorbed most of the last decade of effort. MyoCycle contributed $0.1 million, unchanged.

Gross margin fell to 40.9% from 43.9%. The company points to three causes: higher tariffs, foreign-exchange movements and the 4% revenue-sharing expense owed to Oramed under the March 2026 transaction. The third of those is permanent within the terms of the agreement, which means part of the margin gap will not close simply because volumes recover.

Total operating expenses fell 24% to $6.861 million, but the comparison flatters the quarter: the prior-year period carried $2.783 million of one-time impairment charges. Stripping those out, spending rose, driven by research and development of $1.754 million against $0.767 million, of which $0.7 million was Oratech clinical trial cost. Sales and marketing fell to $3.531 million from $3.785 million and general and administrative fell to $1.576 million from $1.739 million. On the company non-GAAP basis, adjusted operating expenses rose 8% to $6.5 million.

Operating loss narrowed 37% to $4.152 million from $6.563 million, again helped by the absence of the impairment. On the non-GAAP basis the operating loss widened, to $3.778 million from $3.506 million. The two measures point in opposite directions, and the non-GAAP one is the better description of what the operating business did.

The balance sheet at June 30, 2026

Unrestricted cash was $9.448 million, against $2.169 million at December 31, 2025. Including restricted balances the figure is $9.888 million. The company describes a pro-forma position of approximately $11 million, which adds the $1.5 million of the July 6 financing received after the quarter closed. Total assets were $35.000 million against $22.900 million at year end, and shareholders equity was $12.216 million against $8.408 million.

The improvement is financing, not operations. Operating activities consumed $9.680 million in the first half of 2026 against $9.429 million in the first half of 2025, so half-year cash burn did not improve at all. Financing activities provided $10.505 million and investing activities provided $6.472 million, the latter largely from the Oratech transaction. The Q2 2026 Form 10-Q states that these conditions raise substantial doubt about the company ability to continue as a going concern, the same language carried in the annual report.

Balance-sheet details that deserve more attention

• Inventory: $6.151 million at June 30, 2026, against $5.732 million at December 31, 2025. This is substantial relative to quarterly revenue and creates both fulfillment capacity and obsolescence risk.
• Accounts receivable: $7.861 million at June 30, 2026, up from $6.138 million at December 31, 2025 and larger than a full quarter of revenue. Cash conversion matters because reimbursements and capital-equipment sales can have extended collection cycles, and receivables growing faster than revenue is the first place a distribution-led strategy shows strain.
• Debt on the balance sheet: convertible promissory notes of $4.432 million and financing liabilities of $4.083 million at June 30, 2026, neither of which existed at December 31, 2025.
• Customer concentration: one customer represented 51% of the company’s trade-receivable credit exposure at June 30, 2026, down from 56% at December 31, 2025. The same customer accounted for 14.1% of total revenue in the first half of 2026.
• Purchase obligations: $10.696 million of non-cancelable orders at June 30, 2026, all scheduled within one year, primarily for ReWalk systems produced in-house and for AlterG systems built by contract manufacturer Cirtronics. Against $9.4 million of cash at the same date, this commitment is the single largest claim on near-term liquidity.
• Debt and derivative complexity: convertible notes, derivative liabilities and warrant liabilities create both interest expense and non-cash fair-value volatility. Interest expense on debt was $0.352 million in the second quarter and $1.292 million in the first half of 2026, against nothing a year earlier, and the fair-value line swung $6.912 million in a single quarter.
• Accumulated deficit: $284.7 million at the end of 2025, demonstrating that repeated equity raises have funded a long path without cumulative profitability.

14 12. Management, execution and governance

Lifeward’s leadership structure changed again on August 31. Mark Grant left the president, chief executive officer and director roles effective that day. The company said the departure was not caused by a disagreement over operations, policies or practices. He will serve as a senior adviser through September 30 for a $40,000 consulting fee; unvested equity was forfeited and the filing states that no cash severance or extended benefits are payable beyond accrued compensation and the consulting arrangement.

Josh Hexter becomes interim chief executive officer and principal executive officer on September 1. He is Chief Operating and Business Officer of Oramed Pharmaceuticals, Lifeward’s controlling shareholder, and expects to reduce those Oramed responsibilities to about 5% of his current role while serving Lifeward. His agreement provides NIS 100,000 gross per month plus a NIS 5,000 commuting allowance or company car, annual-bonus eligibility and benefits; the arrangement requires shareholder approval at the next general meeting.

Rami Aviram becomes chief financial officer, principal financial officer and principal accounting officer on November 1. Almog Adar remains CFO through September 30, and the company intends to appoint an interim finance officer for the intervening month. Aviram’s agreement provides NIS 70,000 gross per month plus a NIS 5,000 allowance or company car, bonus eligibility and benefits.

The operational task is unchanged: management must convert reimbursement access and channel partnerships into repeatable ReWalk placements, stabilise AlterG revenue and service, manage manufacturing and working capital, and decide how much capital the commercial neurorehabilitation business can devote to the upper-body programme and the POD biomedical pipeline.

Sources: August 31 Form 8-K, company leadership release and August 20 board filing.

15 13. Commercial strategy from here

Build a direct-to-patient funnel for ReWalk

Lifeward’s first priority is to turn coverage into placements. The company’s 2025 restructuring created a hybrid U.S. model organized around direct-to-patient engagement, capital-equipment sales and payer capabilities. A successful funnel should identify eligible candidates earlier, guide them through physician documentation, connect them with training centers and reduce claim errors.

Dedicated clinic days at Shirley Ryan AbilityLab are a practical experiment. They can concentrate patient evaluations, therapist expertise and device demonstrations. The model could be replicated at other major spinal-cord-injury centers if it improves conversion and reduces cycle time.

Use channel partners where a direct model is too expensive

The August 5, 2026 pilot with Ottobock Care is the clearest expression of this idea so far, and the largest network Lifeward has plugged into. Ottobock Care runs more than 50 patient-care clinics across the United States with staff who already fit, train and follow up on complex mobility devices for a living. That is precisely the infrastructure Lifeward cannot afford to build. If the six-month pilot works, the model converts a fixed cost Lifeward has never been able to carry into a variable one it pays only on volume. If it does not, the company has spent six months and learned something, which on a balance sheet this size is not nothing but is not fatal either. The single number to demand when the pilot period ends is units placed through the channel, not clinics enrolled: an enrolled clinic is a logo, a placed unit is revenue.

The Verita Neuro agreement offers a partner-led route into Mexico, Thailand and the United Arab Emirates. Verita’s inpatient programs can integrate device training into an intensive rehabilitation stay. This may be better suited to international self-pay or medical-tourism populations than the slower outpatient reimbursement model used in the United States and Germany.

The advantage is capital efficiency. The risk is limited control over sales quality, patient selection and brand positioning. Lifeward must ensure that ReWalk is presented as a regulated mobility and rehabilitation device, not as proof of neurological restoration.

Restore AlterG growth

AlterG remains Lifeward’s largest product line. Stabilizing sourcing, production and distributor ordering is essential. The company introduced the lower-cost NEO platform to broaden access, but rehabilitation clinics still face capital budgets and competing equipment priorities.

Management needs to show that the 2025 decline and Q1 2026 weakness were temporary timing and working-capital problems rather than declining demand. Investors should watch unit shipments, backlog, service revenue, gross margin and the resumption of international distributor orders.

Reduce device cost and improve gross margin

Lifeward has stated that R&D will include material-cost reductions for ReWalk and AlterG. This is strategically important. Reimbursement creates a ceiling on available revenue per placement, so margin expansion depends on lower component cost, efficient manufacturing, fewer service events, better inventory planning and a shorter sales cycle.

Cloud-connected devices may help predictive maintenance and usage evidence. Data can support payers, improve service and identify whether users remain active after training. The commercial value of connectivity will depend on whether Lifeward turns it into lower costs or stronger reimbursement, not simply whether the feature exists.

16 14. Competitive landscape

Medical exoskeletons compete across several categories: rigid systems for spinal cord injury, clinic-based gait-training robots, soft exosuits and emerging self-balancing personal systems. Competitors and adjacent developers have included Ekso Bionics, Indego-related platforms, Wandercraft, Ottobock-linked technologies and a growing field of research-stage wearable robotics. Ottobock deserves a note of its own here: the group develops mobility technologies that sit adjacent to ReWalk, while its patient-care arm, Ottobock Care, became a Lifeward distribution partner on August 5, 2026. A competitor on the technology side and a channel on the service side is an ordinary arrangement in medical devices, but it does mean the relationship is not one-directional.

ReWalk’s strongest advantages are history, regulatory experience, personal-use clearance, reimbursement infrastructure and an established training network. Its weaknesses are dependence on crutches, selective patient eligibility, slow adoption and a company balance sheet far smaller than many medical-device competitors.

The wheelchair remains the most important functional competitor. Any personal exoskeleton must offer enough incremental health, independence or life-experience value to justify cost and complexity. Future self-balancing systems could improve the category’s utility by reducing reliance on crutches, but they may also raise cost, weight and regulatory risk.

AlterG competes with standard treadmills, aquatic therapy, body-weight-support systems and other rehabilitation equipment. Its differential-air-pressure technology is differentiated, but clinic budgets are finite. ReStore competes with conventional therapy, electrical stimulation, treadmill training and other robotic gait tools.

The upper-body program will face devices ranging from passive arm supports to powered rehabilitation robots. Its commercial opportunity may be larger, but so will the need to prove that assistance translates into useful functional recovery or independence.

17 15. Catalyst map: what can change the Lifeward story

No date has been invented: where the company has not announced one, the table says so explicitly.

18 16. Bull case

The constructive scenario begins with ReWalk finally benefiting from the reimbursement infrastructure built over the previous decade. Traditional Medicare and Medicare Advantage placements grow, BARMER and other German insurers supply a steady base, and dedicated clinical programs reduce the time from inquiry to delivery. ReWalk revenue becomes predictable enough to support manufacturing and reimbursement staff.

AlterG recovers from the 2025 distributor comparison and Q1 2026 working-capital disruption. The Cirtronics transition stabilizes, service revenue supports margins and the lower-cost NEO system opens a broader clinic market. Cost reductions improve gross margin as fixed overhead is spread across higher volume.

The upper-body exoskeleton reaches development and regulatory milestones without a large capital burden. Because post-stroke upper-limb impairment is common, the product addresses a larger population than ReWalk Personal and uses Lifeward’s existing clinical relationships. A credible reimbursement route makes the asset strategically valuable before full commercialization.

The POD platform supplies additional optionality. A well-designed oral-insulin study prospectively validates the patient-selection thesis, allowing Lifeward to seek a pharmaceutical partner. Oramed continues funding and managing development, limiting Lifeward’s direct cash exposure.

Under this scenario, the July capital enables growth rather than merely funding losses. Revenue rises, cash burn falls and the company avoids repeated deeply dilutive financings. Because the current enterprise is extremely small, even modest commercial success could materially change its valuation.

19 17. Bear case

The negative scenario is that reimbursement remains operationally slow. Covered lives increase, but the eligible-patient funnel remains narrow, claims take months and ReWalk revenue stays volatile. The product remains clinically meaningful but commercially subscale.

AlterG does not recover. Clinics defer capital spending, distributors remain inconsistent and manufacturing transitions continue to pressure shipments and margins. Inventory and purchase commitments consume cash before revenue is collected.

The upper-body program takes longer and costs more than the 18-to-24-month target. Regulatory requirements expand, clinical evidence is insufficient or the final product fails to demonstrate compelling workflow economics. ReStore’s limited commercialization becomes a cautionary precedent.

The oral-insulin program fails to validate the retrospective hypothesis from the prior Phase 3 data. Lifeward spends management attention on a drug platform outside its traditional expertise while the core device business remains weak.

Most importantly, the company continues burning cash. Convertible debt, warrants and pre-funded warrants expand the share count, and new capital is raised at lower prices. Reverse splits preserve the Nasdaq listing but do not create value. Basic-market-cap comparisons repeatedly attract investors who underestimate the fully diluted structure.

20 18. Red flags that should not be minimized

Going-concern history

Lifeward entered 2026 with only $2.2 million in cash and an auditor warning about substantial doubt. New capital improves immediate liquidity but does not prove self-sufficiency.

Cumulative dilution

The company has repeatedly used equity, pre-funded warrants, warrants, ATM sales and convertible notes. Two recent reverse splits can obscure the scale of historical dilution.

Secured debt

Recent notes are secured and carry default-rate provisions. Debt holders can have stronger claims than ordinary shareholders in a stressed scenario.

Working-capital strain

Q1 AlterG shipments were affected by working-capital and sourcing constraints. Purchase obligations are large relative to cash and quarterly revenue.

Strategic complexity

The company is simultaneously a rehabilitation-device vendor, wearable-robotics developer and clinical-stage oral-biologics platform. Focus and capital allocation may suffer.

Related-party influence

Oramed holds substantial economic rights, has board affiliations and supplies financing and clinical services. Independent governance remains important.

Coverage is not revenue

Large covered-life figures are useful, but actual placements depend on medical eligibility, documentation, training, authorization and claims payment.

Limited float and financing complexity

A limited free float, concentrated ownership and a large pool of convertible or warrant-linked securities can complicate liquidity, governance and future financing. Those structural constraints should be assessed through filings and fully diluted share counts, not through short-term trading patterns.

21 19. What to monitor each quarter

1. ReWalk revenue and units: distinguish reimbursed placements from demos, rehabilitation units and timing effects.
2. Lead conversion: watch whether direct-to-patient and Shirley Ryan programs shorten the funnel.
3. Accounts receivable and cash collection: revenue quality matters as much as bookings.
4. AlterG shipments: determine whether the 2025 decline and Q1 2026 weakness were temporary.
5. Gross margin: look for evidence that manufacturing transitions and cost-reduction projects are working.
6. Operating cash burn: compare cash use with management’s claims of a path to positive cash flow.
7. Inventory and purchase commitments: excessive inventory can become an expensive warning sign.
8. Basic and fully diluted capitalization: update the share count after every note conversion, warrant exercise and registration statement.
9. Upper-body milestones: insist on specific engineering and regulatory progress rather than repeating the launch target.
10. Oral-insulin trial status: confirm registration and prospective design before assigning value to the asset.
11. Related-party disclosures: review Oramed transactions, services, board relationships and revenue-sharing obligations.
12. Nasdaq compliance: the 2026 reverse split restored the bid price, but sustained compliance still depends on market value and shareholder support.

22 20. Valuation framework without a price target

Lifeward cannot be valued responsibly through a single revenue multiple. It contains several assets with different risk profiles:

• ReWalk: a reimbursed but narrow personal medical-device franchise whose value depends on placement growth and contribution margin.
• AlterG: a broader capital-equipment and service business with a meaningful installed base but recent revenue volatility.
• ReStore and MyoCycle: smaller portfolio products with limited evidence of strategic value at current revenue levels.
• Upper-body exoskeleton: a pre-commercial development option that should be probability-adjusted for technical, regulatory and commercial risk.
• POD/oral insulin: a clinical-stage pharmaceutical option with potentially large upside and equally large scientific uncertainty.
• Capital structure: secured debt, convertible notes, pre-funded warrants, transaction warrants, legacy warrants and revenue sharing that must be deducted or modeled.

A sum-of-the-parts approach is more logical, but only after constructing a fully diluted share count. Investors should model several conversion and exercise scenarios rather than assuming every instrument either converts immediately or disappears. Cash proceeds from warrant exercise can offset dilution, but cashless-exercise provisions, ownership caps and market prices affect the outcome.

The apparent relationship between a roughly $20.9 million basic market cap at the August 17, 2026 Finviz snapshot and $22 million of annual revenue may look compelling. It is not a sufficient valuation argument. The company’s losses, debt, obligations and potential shares explain part of the discount. The opportunity exists only if Lifeward can create enterprise value faster than it creates new claims on that value.

23 21. Bottom line

Lifeward’s history deserves more respect than its stock chart suggests. ReWalk was a legitimate medical breakthrough. It helped create a regulatory category, gave selected people with spinal cord injury a way to stand and walk, and forced payers to confront whether robotic mobility could qualify as a reimbursable medical benefit.

The company also demonstrates why pioneering a category can be financially punishing. ReWalk spent years building technology before reimbursement existed. Each sale required clinical and administrative infrastructure. The eligible market was smaller than headline spinal-cord-injury statistics implied. The business repeatedly raised capital while waiting for policy to catch up.

That policy has now moved. Medicare’s brace classification and $91,031.93 K1007 purchase fee-schedule amount are real. German statutory-insurance contracts are real. ReWalk 7 is a more practical device. Medicare Advantage expansion, Shirley Ryan clinic days and international distribution create a better commercial structure than ReWalk possessed during most of its public history.

But Lifeward is not a clean turnaround. AlterG has not yet produced stable growth or profitability. Cash burn remains high. Manufacturing and working-capital constraints have affected shipments. The Oramed transaction and July financing have made the company better funded but much more complex and potentially dilutive. The POD platform may eventually be valuable, but it also shifts the narrative from a focused medical-device company to a hybrid biomedical micro-cap.

The next phase will be decided by execution rather than invention. Lifeward no longer needs to prove that an exoskeleton can make a paralyzed user walk. It needs to prove that a reimbursed exoskeleton can be sold repeatedly and profitably; that AlterG can generate dependable cash; that an upper-body product can reach market on realistic terms; and that oral insulin can create strategic value without overwhelming the company.

For readers following LFWD, the right stance is neither to dismiss ReWalk as a failed novelty nor to treat every covered-life announcement as the beginning of mass adoption. The technology has earned credibility. The business model is still earning it.

24 Primary and high-quality research sources

1. Leadership transition — August 31, 2026. Lifeward Form 8-K covering Mark Grant’s departure, Josh Hexter’s interim CEO appointment, Rami Aviram’s CFO appointment, compensation and transition terms. SEC filing. Company announcement: official press release.
2. Board changes — August 14-20, 2026. Form 8-K covering the appointments of Yonason Greenwald, Haggai Zamir and Avraham Gabay, Gabay’s appointment as chair and Nadav Kidron’s immediate resignation. SEC filing.
3. Lifeward press release, August 5, 2026 — six-month pilot program with Ottobock Care for the ReWalk 7 Personal Exoskeleton
4. Lifeward 2025 Form 10-K, filed in 2026
5. Lifeward Q1 2026 Form 10-Q
6. Lifeward Form 8-K filed August 14, 2026 — Q2 2026 results, director resignations and chief financial officer departure
7. Exhibit 99.1 — Lifeward second quarter 2026 results press release, August 14, 2026
8. Lifeward Q2 2026 Form 10-Q, quarter ended June 30, 2026
9. Lifeward Form S-3 filed August 3, 2026 — resale of 2,066,662 ordinary shares
10. Lifeward July 2026 Form 8-K — convertible notes and warrants
11. Lifeward July 8, 2026 Form D — exempt financing notice
12. Lifeward investor relations — current SEC filings list
13. Lifeward Q1 2026 financial results and product-revenue detail
14. ReWalk 2014 IPO registration statement — original business history and risk factors
15. ReWalk 2015 Form 10-K — completed 2014 IPO terms and net proceeds
16. FDA de novo database — ReWalk powered exoskeleton
17. FDA 510(k) database — ReWalk ReStore
18. FDA 510(k) database — ReWalk 7
19. Lifeward/ReWalk release — 2023 stair and curb clearance
20. CMS final 2024 HCPCS K1007 payment determination
21. Federal Register — CY 2024 Medicare brace-benefit rule for personal exoskeletons
22. Lifeward release — implementation of the 2024 Medicare payment rate
23. Lifeward release — BARMER reimbursement agreement
24. ReWalk release — AlterG acquisition terms
25. Lifeward FY2025 financial results
26. Lifeward release — upper-body exoskeleton acquisition
27. Lifeward Form 8-K — closing of the Oratech/Oramed transaction
28. Lifeward release — Verita Neuro distribution agreement
29. Peer-reviewed meta-analysis of powered exoskeleton use after spinal cord injury
30. Peer-reviewed study of ReWalk home and community use
31. Implementation review — barriers and facilitators to exoskeleton use
32. Scoping review of exoskeleton outcomes and evidence gaps